Related Experiment Video

Updated: Jun 18, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Relevance of genetic polymorphisms in inflammatory response to percutaneous coronary intervention

Nawzad Saleh1, Alexander Kovacs, Per Tornvall

  • 1Department of Cardiology and Atherosclerosis Research Unit, King Gustaf V Research Institute, Stockholm, Sweden. nawzad.saleh@karolinska.se

Scandinavian Journal of Clinical and Laboratory Investigation
|November 26, 2009
PubMed

Insights

Genetic variations in CRP and IL-6 genes do not appear to influence the inflammatory response following percutaneous coronary intervention (PCI). This suggests other factors contribute to inter-individual differences in inflammation after PCI procedures.

Area of Science:

  • Cardiovascular Medicine
  • Genetics
  • Immunology

Background:

  • Percutaneous coronary intervention (PCI) triggers an inflammatory response, with markers like C-reactive protein (CRP) and interleukin-6 (IL-6) increasing in plasma.
  • The extent of this inflammatory response correlates with restenosis risk and shows significant inter-individual variability.
  • Stent implantation during PCI is a known factor influencing this response, but underlying reasons for variation remain largely unknown.

Purpose of the Study:

  • To investigate the association between specific single nucleotide polymorphisms (SNPs) in the CRP (-286) and IL-6 (-174) gene promoter regions and the inflammatory response to PCI.
  • To determine if genetic variations in CRP and IL-6 influence plasma levels of these inflammatory markers post-PCI.

Main Methods:

  • Genotyping of patients for the CRP -286 and IL-6 -174 promoter SNPs.
  • Measurement of plasma CRP and IL-6 levels using area-under-the-curve (AUC) up to 72 hours post-PCI.
  • Statistical analysis to assess the correlation between SNPs and inflammatory marker levels.

Main Results:

  • No significant association was found between the CRP -286 SNP and plasma CRP levels after PCI.
  • No significant association was observed between the IL-6 -174 SNP and plasma IL-6 levels after PCI.
  • The study results indicate that these specific genetic variations do not play a major role in the inflammatory response to PCI.

Conclusions:

  • Genetic variations within the CRP and IL-6 promoter regions studied are unlikely to be the primary drivers of inter-individual differences in the inflammatory response to PCI.
  • Further research is needed to identify other genetic or non-genetic factors contributing to the variable inflammatory response observed after PCI and stent implantation.

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...